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ABSTRACT
MicroRNAs (miRNAs) guide Argonaute (Ago) pro-
teins to distinct target mRNAs leading to transla-
tional repression and mRNA decay. Ago proteins in-
teract with a member of the GW protein family, re-
ferred to as TNRC6A-C in mammals, which coor-
dinate downstream gene-silencing processes. The
cytoplasmic functions of TNRC6 and Ago proteins
are reasonably well established. Both protein fami-
lies are found in the nucleus as well. Their detailed
nuclear functions, however, remain elusive. Further-
more, it is not clear which import routes Ago and
TNRC6 proteins take into the nucleus. Using differ-
ent nuclear transport assays, we find that Ago as well
as TNRC6 proteins shuttle between the cytoplasm
and the nucleus. While import receptors might func-
tion redundantly to transport Ago2, we demonstrate
that TNRC6 proteins are imported by the Importin-
pathway. Finally, we show that nuclear localization of
both Ago2 and TNRC6 proteins can depend on each
other suggesting actively balanced cytoplasmic Ago
– TNRC6 levels.
INTRODUCTION
Argonaute proteins are binding modules for small regula-
tory RNAs and thus essential for all small RNA-guided
gene silencing pathways (1,2). Phylogenetically, Argonaute
proteins are organized in three clades: the Ago clade, the
Piwi clade and the worm-specific Wago (or Sago) clade.
In Caenorhabditis elegans, 26 different Argonaute proteins
exist and among them the Wago proteins fulfill very spe-
cialized functions such as binding of secondary siRNAs
or transport of siRNAs from the cytoplasm to the nucleus
(3–5). The expression of Piwi proteins is restricted to the
germline where they bind to Piwi interacting RNAs (piR-
NAs), which guide the repression ofmobile genetic elements
during germ cell development (6).
Ago clade members (referred to as Ago proteins here-
after) are ubiquitously expressed and interact with short in-
terferingRNAs (siRNAs) ormiRNAs (1,7). Inmany organ-
isms, siRNAs can originate from exogenous or endogenous
sources (endo- or exo-siRNAs) (8,9). SiRNAs guide Ago
proteins to complementary sequences leading to cleavage of
the target site by the bound Ago protein. Animal miRNAs,
in contrast, guide Ago proteins to only partially comple-
mentary target sites mainly located in the 3′ untranslated
region (UTR) of mRNAs (10). Ago proteins interact with a
member of the GW protein family, which are characterized
by glycine-tryptophan repeats and some specific GW-pairs
serve as binding platform for Ago proteins (11–17). The C-
terminal half of GW proteins is referred to as the silenc-
ing domain because it coordinates all downstream steps of
miRNA-guided gene silencing. First, it interacts with the
poly(A) binding protein located on the poly(A) tail of the
mRNA leading to inhibition of translational initiation. Sec-
ond, it recruits deadenylases (e.g. the CCR4/NOT complex)
to the poly(A) tail to remove it (18). To facilitate silencing,
components of the CCR4/NOT complex recruit the trans-
lational repressor DDX6 to the mRNA (19,20). Finally, the
shortened poly(A) tail functions as trigger for the decapping
complex to remove the 5′ cap of the mRNA leading to rapid
degradation by 5′ to 3′ exoribonucleases such as Xrn1. At
early stages of silencing, translational inhibition dominates
whereas at later stages mRNA decay is the predominant si-
lencing process (21–23).
Ago proteins are composed of several domains with dis-
tinct functions (24). The N domain is required for duplex
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unwinding but also contributes to the endonucleolytic ac-
tivity of Ago proteins (25–28). The PAZ domain binds the
3′ end and the MID domain the 5′ end of the small RNA
(29–34). The PIWI domain is the endonuclease domain and
harbors the catalytic center composed of DEDH (35–37).
In mammals, only Ago2 possesses catalytic activity and is
therefore often referred to as slicer (38,39). In addition,
Ago2 seems to be the most abundant Ago protein in many
mammalian cell types followed by Ago1, 3 and 4 (40,41).
Although miRNA-guided gene silencing is a cytoplas-
mic process, both miRNAs and Ago proteins have been
found in the nucleus of mammalian somatic cells as well
(5,42). They have been implicated in various nuclear pro-
cesses including transcriptional silencing processes, DNA
repair mechanisms or alternative splicing. It was shown that
Ago proteins can be directed to promoters by transfection
of promoter-specific siRNAs leading to transcriptional si-
lencing or activation (43–45). SiRNAs against nuclear tar-
get RNAs have also been widely used and nuclear RNAs
can be knocked down efficiently (46,47). However, despite
the numerous publications, nuclear Ago functions are still
debated. This might by due to the fact that Ago proteins
mainly localize to the cytoplasm in immunofluorescence ex-
periments although minor portions are also seen in the nu-
cleus when endogenousAgo2 is stained (46,48). In addition,
Ago proteins are frequently found in nuclear fractions in
biochemical fractionations. Such fractionations might of-
ten be inherently contaminated with nucleus associated cy-
toplasmic components and this might even be unavoidable.
Not only Ago proteins but also TNRC6 proteins have been
found to localize to the nucleus under specific conditions
(17,49). It has been demonstrated that TNRC6A contains
a nuclear localization signal (NLS) as well as a nuclear ex-
port signal (NES) and by mutation of the NES, TNRC6A
remains in the nucleus where it is enriched in distinct foci
demonstrating that at least TNRC6A shuttles between the
nucleus and the cytoplasm (49).
Although it has been suggested that Importin-8 (Imp8) is
involved in the nuclear localization of Ago2 (50,51), the re-
quirements for nuclear transport for Ago as well as TNRC6
proteins have not been thoroughly investigated. Here, we
analyzed nuclear localization and transport of Ago2 as well
as the TNRC6 proteins. Using different assays, we find that
Ago as well as TNRC6 proteins shuttle between the cyto-
plasm and the nucleus. However, we are not able to assign
one specific import receptor to Ago2 and thus suggest that
Importins may function redundantly in this process. Inter-
estingly, TNRC6A is transported by the Importin-/ fam-
ily of import receptors and uses a different route into the
nucleus as Ago2. Furthermore, both proteins affect nuclear
import of the respective interaction partner suggesting a
model in which the Ago and TNRC6 protein families bal-
ance each other’s cytoplasmic levels by nuclear import.
MATERIALS AND METHODS
Cell lines, cell culture and generation of stable cell lines
HeLa, HEK 293T, NIH 3T3, LN-229, T98G, U-87 MG,
U-2 OS, HCT116, Hep G2, HuH-7, A549, H1299, MCF7,
T-47D, NCCIT, MRC-5, DU 145, GM5756, Ntera2 and
Sk-Mel-28 cells were cultivated in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS) and Penicillin/Streptomycin (P/S) an-
tibiotics mix (all from Sigma). Arpe-19 was cultivated in
DMEM/F12 (1:1) + 10% FBS + P/S (all from Sigma).
DLD-1 and LNCaP were cultivated in RPMI-1640 +
10% FBS + P/S (all from Sigma). Human pulmonary
artery smoothmuscle cells (HPASMC) and endothelial cells
(HPAEC)were purchased fromLonza and cultured in basal
medium SmBM (HPASMC) and EBM-2 (HPAEC) supple-
mented with growth factors from SingleQuots Kit and 10%
FBS (all from Lonza). Primary keratinocytes were isolated
as described previously (52) and cultured in a 1:1 mixture of
KSF-M and Medium 154 for keratinocytes, supplemented
with epidermal growth factor and bovine pituitary extract
(all fromGibco). Flp-In T-REx 293 cell line (Life Technolo-
gies) was cultivated inDMEM+10%Tetracycline-free FBS
(Clontech) + P/S + 100 g/ml Zeocin (Life Technologies)
+ 15 g/ml Blasticidin (Applichem).
For generation of stable inducible Flp-In T-REx 293
cell lines, cells were grown for 24 h without Zeocin and
Blasticidin until transfection. Cells were cotransfected with
pOG44 and pcDNA5-FRT/TO in a 9:1 ratio in 6-well for-
mat and split to one 10 cm plate one day post-transfection.
Selection was started 2 days post-transfection by splitting
cells into two 15 cm plates and addition of 15 g/ml
Blasticidin and 200 g/ml Hygromycin B (Life Technolo-
gies). Clones were picked two weeks later and tested for
Zeocin sensitivity, inducibility and expression levels. Ex-
pression was induced for 24 h with 1 g/ml Tetracycline
(Sigma–Aldrich). Stable clones weremaintained in the same
medium as used for selection.
For generation of stable monoclonal HeLa cell line ex-
pressing FH-SV40NLS-Ago2, HeLa was transfected with
pIRES-Flag/HA-SV40NLS-Ago2 in 6-well format. Cells
were split 1 day post-transfection into one 15 cm plate
and selection was started with 400 g/ml G418 (GE
Healthcare/PAA). Clones were picked 4 weeks after trans-
fection and tested for expression by Western Blot and im-
munofluorescence. Stable clones were maintained in the
same medium as used for selection.
Immunofluorescence stainings, microscopy and quantifica-
tions
For immunofluorescence stainings, cells were washed once
with PBS and fixed with 4% paraformaldehyde in PBS for
10 min at 37◦C. Fixation was stopped by adding PBS + 100
mM glycine for 5 min. Cells were then washed once with
PBS and permeabilized with PBS + 0.1% Triton X-100 for
30 min. After washing again with PBS, cells were blocked
with PBS+ 0.01%TritonX-100 + 5%BSA for 30min. First,
antibody incubationwas done in PBS+ 0.01%TritonX-100
+ 5% BSA for 1 h at room temperature. After three washing
steps with PBS + 0.01%Triton X-100 + 5%BSA, secondary
antibody was added for 1 h at room temperature. Cells were
then washed once with PBS + 0.01% Triton X-100 + 5%
BSAand trice with PBS andmounted using ProlongGold+
DAPI (Life Technologies). Confocal microscopy was done
on aTCSSP8 (LeicaMicrosystems) equippedwith acousto-
optical beam splitter, 405 nm laser (for DAPI), argon laser
(488 nm for Alexa 488 and GFP) and DPSS laser 561 nm
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(for Alexa 555). All images were recorded using objective
HC PL APO 63x/1.30 GLYC CORR CS2 and focusing to
the z-section with the largest nucleus diameter. Images for
quantifications were recorded with HyD SP GaAsP detec-
tors (Leica Microsystems). Quantifications were done from
tif files exported from LAS AF software. Quantification
was automated using Cell Profiler v. 2.1.0 (53). We calcu-
lated nucleo-cytoplasmic ratios from mean signal values of
z-sections derived from nuclear and cytoplasmic compart-
ments. Thus, this method does not measure total nuclear
or cytoplasmic protein levels in the context of the total vol-
ume of a cell. Nuclear and cytoplasmic TNRC6 foci were
manually counted from 100 randomly picked cells per sam-
ple and cells were classified into cells with nuclear (>80% of
TNRC6 in the nucleus), intermediate or cytoplasmic (>80%
of TNRC6 in the cytoplasm) phenotype. For figure images,
representative cells were selected, picture was cropped and
contrast was increased to the same extent for all pictures of
one panel.
Heterokaryon assays and Leptomycin B treatments
2 × 105 HeLa cells or stable monoclonal HeLa FH-NLS-
Ago2 were plated on cover slips in 24-well plates one day
before assay. Two hours before addition of NIH 3T3 cells,
medium was changed to DMEM + 1% FBS + P/S + 75
g/ml cycloheximide (Sigma–Aldrich). 4 × 104 cells NIH
3T3 were added to each well and co-cultured with HeLa for
2–4 h until attachment. Cells were then treated with 1 ml
PBS+ 50% (w/v) polyethylene glycol 1500 (Sigma–Aldrich)
for 2 min at room temperature followed by five washing
steps with PBS. Then, DMEM+1%FBS+ P/S + 75g/ml
cycloheximide was added again to cells for 4 h. Assay was
stopped by adding PBS + 4% paraformaldehyde. For detec-
tion of endogenousAgo2 or FH-NLS-Ago2, cells were used
for immunofluorescence staining as described above.
Leptomycin B was purchased from Cayman Chemicals
as 0.1 g/l solution in ethanol. Leptomycin B was added
to cells to 10 ng/ml final concentration in standard cultiva-
tion medium. Ethanol was added to control cells without
Leptomycin B. Treatments were done for 4 h and stopped
by addition of PBS+ 4%paraformaldehyde and subsequent
immunofluorescence staining.
In vitro transcription/translation and GST pulldown assays
GST or GST-Importins were allowed to bind to
glutathione-sepharose 4B (GE Healthcare). GST-Importin
pulldown assays were carried out with purified GST as
a negative control as described before (54). One hundred
microliters beads were pre-equilibrated in IP-buffer [20
mM HEPES pH 7.5/100 mM KOAc/112.5 mM NaCl/0.5
mMEGTA/5 mMMgOAc/250mM sucrose] at 4◦C, mixed
with 15gGST-fusion proteins with or without His-tagged
Importin- and incubated at 4◦C for 1 h. The TNRC6A,
TNRC6B, TNRC6C coding sequences – either wildtype or
mutated – were transcribed and translated in vitro (IVTT)
in the presence of [35S]-methionine (Hartmann Analytic)
using TNTCoupled Reticulocyte Lysate System (Promega)
according to the manufacturer’s protocol from pET28a
constructs. After incubation with or without purified
Ago2 or Nucleoplasmin, 10 l of the IVTT reaction batch
were allowed to bind to the immobilized fusion proteins.
After washing three times with IP-buffer, sepharose beads
were dissolved in 60 l protein sample buffer. Twenty
microliters of the reaction were separated by SDS-PAGE
and visualized by Coomassie Brilliant Blue staining. For
input lanes, 0.5, 5 or 10% of IVTT used for pulldowns was
loaded. To detect the [35S]-labeled proteins, dried gels were
autoradiographed for 16–24 h. Binding was visualized by
analyzing data with a CR 35 BIO (Du¨rr Medical) and the
Aida Image Analyser v.4.27 (Raytest).
Antibodies
Monoclonal antibodies against the RRM domain of
TNRC6A, TNRC6B and TNRC6C were generated by im-
munization of rats with recombinant purified RRM do-
mains. Immunization of rats and isolation of hybridoma
clones was done as described previously (55). This revealed
a TNRC6B specific clone (6G3) and a clone, which recog-
nizes all three human TNRC6 proteins (7A9). The poly-
clonal antibody against human Ago2 (1562) was gener-
ated by repeated injection of GST-Ago2-1–47 into rabbits.
Serum was generated as described (50).
Following antibodies were used for western: rat-anti-
Ago2 (monoclonal, clone 11A9, hybridoma supernatant
(HS), 1:20, (48)), rabbit-anti-Ago2 (polyclonal, #1526,
blood serum, 1:1.000), rat-anti-TNRC6B (monoclonal,
clone 6G3, HS, 1:10), mouse-anti-Tubulin (monoclonal,
1:10.000, Sigma, clone DM 1A), mouse-anti-HA (mono-
clonal, 1:1000, Covance, clone HA.11), mouse-anti-GFP
(monoclonal, 1:1000, Roche, clones 7.1/13.1), rabbit-anti-
c-Myc (1:1000, Sigma–Aldrich), rabbit-anti-Crm1 (mono-
clonal, 1:500, Santa Cruz Biotechnology, H-300). As sec-
ondary antibodies for Western, goat-anti-rabbit/mouse/rat
IRDye 680 or 800 antibodies (Li-Cor Biosciences) were
used. For Figure 7D, mouse-anti-HA (monoclonal, 1:100,
Cell Signaling) and goat-anti-mouse IgG-HRP (1:2000,
DAKO) were used.
Following antibodies were used for immunofluores-
cence stainings: rat-anti-Ago2 (monoclonal, clone 11A9,
HS, 1:10), rat-anti-TNRC6B (monoclonal, clone 6G3,
HS, 1:10), rat-anti-TNRC6ABC (monoclonal, clone 7A9,
HS, 1:10), mouse-anti-HA (monoclonal, 1:400, Cov-
ance, clone 16B12), chicken-anti-Lsm4 (polyclonal, 1:500,
Sigma–Aldrich, GW22314F), rabbit-anti-YB1 (polyclonal,
1:400, Abcam, ab12148), mouse-anti-RPA194 (mono-
clonal, 1:250, Santa Cruz Biotechnology, C-1), mouse-
anti-RPB1 CTD (monoclonal, HS, 1:10, clone 8WG16,
kindly provided by Dirk Eick), rabbit-anti-Coilin (poly-
clonal, 1:50, Santa Cruz Biotechnology, H-300), mouse-
anti-SC35 (monoclonal, 1:500, abcam ab11862), mouse-
anti-p54nrb (monoclonal, 1:200, BD Biosciences, clone 3),
mouse-anti-PML (polyclonal, 1:100, Santa Cruz Biotech-
nology, H-238), rabbit-anti-HSF1 (monoclonal, 1:400, Cell
Signalling, D3L8I), rabbit-anti-CBP80 (polyclonal, 1:100,
Abcam, ab42389), rabbit-anti-CNOT7 (1:100, (56)), rabbit-
anti-SKIV2L2 (polyclonal, 1:100, Novus Biologicals),
rabbit-anti-Xrn2 (1:400, (57)), mouse-anti-ubiquitin (mon-
oclonal, 1:500, Sigma, clone 6C1), mouse-anti-proteasome
20S a1,2,3,5,6,7 (monoclonal, 1:100, Enzo Life Sciences,
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MCP231), mouse-anti-gH2AX (monoclonal, 1:100, Milli-
pore, clone JBW301), rabbit-anti-53BP1 (polyclonal, 1:100,
Novus Biologicals), rabbit-anti-HSF1 (polyclonal, 1:500,
Cell Signalling, 4356). All primary antibodies are raised
against the human proteins. As secondary antibodies, Alexa
Fluor 488 or Alexa Fluor 555 coupled secondary antibod-
ies goat-anti-mouse/rat/rabbit/chicken were used as 1:400
dilution (Life Technologies).
Statistical analyses
Statistical analyses have been performed for the data pre-
sented in Figures 1C, E, F, H, I, J, 2B-E, 3D, 4B-C, 6B.
Experiments were performed in three biological replicates.
Mean values and standard error of the mean were calcu-
lated from biological replicates. Error bars display standard
error of the mean. Statistical significance was calculated us-
ing two-sided Student’s t-test for unequal sample variance.
P-values <0.05 were considered as significant.
RESULTS
Nucleo-cytoplasmic distribution of human Ago2
In immunofluorescence stainings, most Ago2 is located to
the cytoplasm of the cell. To find a suitable cell system to
study nuclear Ago2 transport and to test whether Ago2
localization varies between cell lines, we stained endoge-
nous Ago2 in various cell lines (Supplementary Figure S1).
Most cell lines appeared to express Ago2 very similarly with
the majority in the cytoplasm and a minor portion in the
nucleus. However, also the minor nuclear signal is Ago2-
specific since Ago2 knock down leads not only to a reduc-
tion of the cytoplasmic but also the nuclear pool ((48) and
see below). Of note, Ago2 is also found in the nuclear frac-
tion of HeLa cell lysates (see Figure 3E).
To further solidify that Ago2 is indeed found in the nu-
cleus, we applied a modified heterokaryon assay, in which
mouse NIH 3T3 cells are fused with HeLa cells and human
Ago2 redistribution into the mouse nucleus is investigated
(Figure 1A). The shuttling protein hnRNPA1 served as pos-
itive control and was detectable in the mouse nucleus after
cell fusion (Figure 1B, top). HnRNPC was used as nega-
tive control and remained solely in the human nucleus (Fig-
ure 1B, bottom). When endogenous Ago2 was analyzed, we
found that human Ago2 levels increased slightly but clearly
measurable over background signal in the mouse nucleus
(Figure 1C) indicating that human Ago2 reaches the mouse
nucleus. Similar results were obtained when eGFP-tagged
Ago2 was analyzed (Supplementary Figure S1D). Whether
it shuttles from the human nucleus or whether it is redis-
tributed from the cytoplasm is unclear. To test this further,
we fused Ago2 to the strong SV40 NLS and forced it into
the nucleus.When these cells were fused withNIH 3T3 cells,
SV40 NLS-Ago2 still appeared in the mouse nucleus al-
though cycloheximide has been added and synthesis of new
proteins can be excluded (Figure 1D, upper panel). Never-
theless, the nuclear pool found in mouse nuclei after fusion
can still originate from the small cytoplasmic SV40 NLS-
Ago2 pool (Figure 1E). However, when cells were treated
with leptomycin B (LMB), which is an inhibitor of Crm-
1-mediated nuclear export (58), before fusion, significantly
less nuclear SV40 NLS-Ago2 was found in the mouse nu-
cleus (Figure 1D, lower panel and 1F for quantification)
demonstrating that NLS-Ago2 indeed shuttles from the hu-
man to the mouse nucleus. To further solidify the observed
nucleo-cytoplasmic shuttling activity of Ago2, we treated
HeLa (Figure 1G andH and Supplementary Figure S2) and
another cell line, Sk-Mel-28, with LMB (Figure 1H). Sk-
Mel-28 is a melanoma-derived cell line with high levels of
nuclear Ago2 (Supplementary Figure S1). Under these con-
ditions, the nuclear Ago2 pool increased significantly, sug-
gesting that endogenous Ago2 shuttles between the nucleus
and the cytoplasm but is mainly localized to the cytoplasm
under steady-state conditions (Figure 1G right panel and
1H for quantification). RNA interference (RNAi) against
Ago2 decreased both the cytoplasmic as well as the nu-
clear signal showing that the observed signal is indeed en-
dogenous Ago2 and not caused by antibody cross reactivity
(Figure 1I and J). Consistent with these observations, Crm1
knock down increased nuclear Ago2 staining (Supplemen-
tary Figure S3A). Thus, our data show that human Ago2 is
able to enter the nucleus and most likely shuttles between
the nucleus and the cytoplasm with only a minor portion
being found in the nucleus under steady state conditions.
Nuclear transport of human Ago2
It has been suggested that Imp8 is involved in the nuclear
transport ofAgo2 (50,51). To test the requirement of import
receptors for nuclearAgo2 localization, we established a nu-
clear RNAi activity assay, in which the nuclear RNA 7SK
is knocked down (Figure 2A). 7SK is part of a nuclear ri-
bonucleoprotein particle involved in the regulation of tran-
scriptional elongation (59). To validate this system, we de-
pleted Ago1–4 (Figure 2B) and analyzed 7SK knock down
efficiency (Figure 2C). Indeed, only when Ago2 is depleted,
the 7SK knock down is reduced demonstrating that the
measured effects are Ago2-dependent and the assay is suit-
able for the analysis of Ago2 import routes. Subsequently,
we knocked down Imp, Imp3–5, Imp7–9, Imp11–13 and
transportin-1 (Tnpo1) (Figure 2D for knock down efficien-
cies). However, none of the tested knock down conditions
resulted in a reproducible change in 7SK knock down effi-
ciency (Figure 2E). Thus, we conclude that at least in this
nuclear RNAi assay, knock down of a single import recep-
tor is not sufficient to prevent nuclear Ago transport. It is
conceivable that several import receptors function redun-
dantly in transporting Ago proteins into the nucleus as has
been reported for human Dicer, for example (60).
Nuclear localization of the human TNRC6 proteins
It has been demonstrated that TNRC6 proteins can localize
to the nucleus under specific conditions (17,49). TNRC6A,
for example, contains an NES and when mutated, over ex-
pressed and tagged TNRC6A accumulates in nuclear foci of
unknown origin (49). To analyze TNRC6 protein transport
in molecular detail, we expressed FLAG/HA-tagged (FH)-
TNRC6A-C and treated the cells with LMB for Crm1-
dependent nuclear export inhibition (Figure 3A). We ob-
serve that all three TNRC6 proteins accumulate in nuclear
foci uponLMB treatment. This is a clear andwidespread ef-
fect as shown by quantification of nuclear and cytoplasmic
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Figure 1. Ago2 is imported into the nucleus of human cells and shuttles between the nucleus and the cytoplasm. (A) Classical and modified heterokaryon
assays. (B) HeLa cells transfected with FH-hnRNPA1 and FH-hnRNPC were fused to mouse NIH 3T3 cells. After fusion, FH-hnRNPA1 appears in the
mouse nucleus characterized by intense DAPI staining from densely packed pericentromeric heterochromatin. FH-hnRNPC does not shuttle and remains
in the human nucleus. (C) HeLa cells treated with cycloheximide were fused to mouse NIH 3T3 cells and endogenous Ago2 was detected with amonoclonal
anti-Ago2 antibody. Microscopy shows Ago2 staining in unfused HeLa cells (upper panels) and no signal in unfused NIH 3T3 cells (middle panels). After
fusion, Ago2 is detected in heterokaryon cytoplasm and both human and mouse nuclei (lower panels). Diagram on the right shows quantification of Ago2
signal from human and mouse nuclei before and after cell fusion with data normalized to human nucleus. (D) Heterokaryon assays were performed with
HeLa cells stably transfected with FH-SV40NLS-Ago2 with or without Leptomycin B treatment. Ago2 was detected by anti-HA antibody staining. (E)
Nuclear and cytoplasmic levels of FH-NLS-Ago2, which was detected with an anti-HA antibody and quantified from nucleus and cytoplasm before fusion
with mouse NIH 3T3. (F) Quantification of Ago2 signal from human and mouse nuclei before and after fusion of untreated or Leptomycin B treated cells
shown in Figure 1D. Quantification was performed as described in Figure 1C. (G) HeLa cells were untreated or treated with Leptomycin B and endogenous
Ago2 was detected with anti-Ago2 antibody. Upper panels show cells transfected with a control siPool, lower panels show cells transfected with a siPool
against Ago2. (H) Signal quantification from untreated or Leptomycin B treated HeLa (left panel) and Sk-Mel-28 (right panel) cells. Ago2 signal intensity
was detected in the nucleus and cytoplasm and nucleus-to-cytoplasm ratio was calculated. (I) Ago2 protein levels were analyzed upon knockdown of
Ago2 or transfection of a control siPool with two different antibodies. Western Blot with anti-Tubulin antibody was used as loading control. Signal
quantifications of knockdown versus control were normalized to Tubulin and shown with standard error of the mean. (J) Nuclear and cytoplasmic Ago2
pools are equally reduced by RNAi against Ago2. Ago2 signal was quantified from nucleus and cytoplasm in untreated or Leptomycin B treated cells upon
knockdown of Ago2 or transfection of a control siPool. Signals were normalized to control siPool. Western blot below shows Ago2 expression in untreated
(lanes 1, 3) or Leptomycin B treated (2, 4) cells after transfection of a control siPool (1, 2) or Ago2 (3, 4) siPool. Tubulin was detected loading control.
Error bars represent standard error of the mean (SEM). *P < 0.05; ***P < 0.0005.
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Figure 2. Ago2 nuclear import is presumably mediated by several redundant import receptors. (A) Schematic representation of the experimental procedure
to measure nuclear Ago2 activity upon Importin knock down. Nuclear Ago2 activity was determined from knock down efficiency of the nuclear 7SK
snRNA. (B) Knock down efficiency of Ago1–4 was determined by quantitative real-time PCR. Data were normalized to GAPDH mRNA and control
siRNA transfected sample. (C) Knock down of human Ago1–4 followed by knock down of 7SK snRNA. Lower panels show Northern Blots probed
for 7SK and U6 snRNAs. 7SK signal was normalized to U6 in the corresponding sample and control siRNA transfected sample (upper panel). (D) An
Importin siRNA library targeting each human Importin, except for Imp, was generated and validated for knock down efficiency by quantitative real-time
PCR. Except for Imp4, two siRNAs (si1, si2) were generated for each Importin. Data were analyzed as described in Figure 2B. (E) The Importin siRNA
library was used to knock down human Importins followed by analysis of 7SK knock down efficiency as described in (A). Data were analyzed as described
in (B).
foci (Figure 3A, panel below left). All three full-length pro-
teins were readily detectable in Western blots (Figure 3A,
below right). Co-staining with marker proteins for diverse
nuclear compartments, complexes and other structures did
not show any co-localization with TNRC6A. Only Ago2
is occasionally found in theses nuclear TNRC6A bodies
(Supplementary Figure S4). Over expression of proteins can
sometimes cause unspecific localization. Thus, we gener-
ated monoclonal antibodies against TNRC6B in order to
analyze endogenous protein. In biochemical fractions of
nuclear and cytoplasmic extracts, TNRC6B was found in
both compartments (Figure 3B). Next, we performed LMB
treatment experiments as described above (Figure 3C and
D). Strikingly, LMB treatment caused a nuclear accumu-
lation of endogenous TNRC6B although not in such dis-
crete foci as observed with over expression of TNRC6B, a
phenomenon that is also observed for cytoplasmic P-bodies
when Ago or TNRC6 proteins are over expressed (61).
Crm1 knock down resulted in similar effects (Supplemen-
tary Figure S3B). The signal is highly specific to TNRC6B
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Figure 3. Human TNRC6 proteins shuttle between the nucleus and cy-
toplasm. (A) HeLa cells transfected with FH-TNRC6A, FH-TNRC6B
or FH-TNRC6C were left untreated or treated with Leptomycin B and
TNRC6 proteins were detected with anti-HA antibodies. Diagram be-
low shows the percentage of cells with cytoplasmic foci, nuclear foci
or cells with foci in both compartments (intermediate) with or without
since knock downusing a siPool (62) against TNRC6B (Fig-
ure 3E for knock down validation) resulted in a complete
loss of the signal (Figure 3C andD). Thus, we conclude that
all three TNRC6 proteins shuttle between the nucleus and
the cytoplasm and their export route is Crm1-dependent.
TNRC6 protein import requires Importin-
To assess how TNRC6 proteins are imported into the nu-
cleus, we knocked down a series of import receptors and
analyzed TNRC6Anuclear localization (Figure 4). As a test
system for nuclear import of TNRC6 proteins, we utilized
a TNRC6A variant containing a mutated NES (TNRC6A
NES-mut), which is trapped in the nucleus (49). Two days
after transfection of the individual siRNAs (see Figure 2),
TNRC6A NES-mut was induced and its localization an-
alyzed (Figure 4A and Supplementary Figure S5). While
knock down of most import receptors did not lead to a
cytoplasmic retention of TNRC6A NES-mut, depletion of
Imp caused a predominant cytoplasmic localization of
over expressed TNRC6A NES-mut suggesting nuclear im-
port by Imp (Figure 4A, right panel for quantification). To
further verify these observations, we analyzed localization
of endogenous TNRC6B uponLMB treatment (Figure 4B).
Strikingly, endogenous TNRC6B trapped in the nucleus
after LMB treatment, but not when Imp was depleted.
Taken together, our results demonstrate that TNRC6 pro-
teins enter the nucleus in an Imp-dependent pathway. Al-
though we did not observe effects of Imp on Ago local-
ization in our previous experiments (Figure 2), we asked
whether at least a small fraction of Ago2 could be co-
transported together with TNRC6B. Upon LMB treat-
ment, the nuclear Ago2 signal increased (Figure 4C). How-
ever, unlike TNRC6B, Imp knock down had no effect on
nuclear Ago2 accumulation under these conditions indicat-
ing that both gene-silencing components are imported into
the nucleus by different transport routes.
TNRC6 proteins interact with Imp
In the canonical Imp pathway, Imp binds the NLS of
cargo proteins and recruits Imp, which facilitates nuclear
import whereas non-canonical import by Imp can be me-
diated by direct interaction with cargo proteins (63,64). To
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Leptomycin B treatment. Western Blot shows expression of FH-tagged
TNRC6A-C (lanes 2–4) or empty plasmid (lane 1) with Tubulin as load-
ing control. (B) Whole cell lysate (WCL, lane 1), cytoplasmic (Cyt, lane 2)
and nuclear (Nuc, lane 3) extracts were prepared from HeLa cells and en-
dogenous TNRC6B or Ago2 were detected byWestern Blotting. Tubulin
and Lamin A/C were detected as cytoplasmic and nuclear controls. (C,
D) Endogenous TNRC6B was detected with a monoclonal anti-TNRC6B
antibody in control siPool or TNRC6B siPool transfected cells with (up-
per panels) or without (lower panels) Leptomycin B treatment. TNRC6B
signal intensity was detected in the nucleus and cytoplasm and nucleus-
to-cytoplasm ratio is shown in (D). (E) TNRC6B and Ago2 protein levels
were detected withmonoclonal antibodies upon knock down of TNRC6A,
TNRC6B, TNRC6C or all three TNRC6 proteins (lanes 1–4). Control
siPool transfected cells (lane 5) or untransfected cells (lane 6, untransf.)
were used as control. Western Blot with an anti-Tubulin antibody was
used as loading control. Error bars represent standard error of the mean
(SEM). ***P < 0.0005.
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Figure 4. Nuclear import of TNRC6 proteins is facilitated by Importin-. (A) HEK 293T cells with stably integrated and inducible myc-GFP-TNRC6A
NES-mut were transfected with Importin siRNAs. Expression of nuclear-trapped myc-GFP-TNRC6A NES-mut was induced 1 day before analysis. Di-
agram on the right shows percentage of cells with cytoplasmic or nuclear GFP foci and cells with foci in both compartments (intermediate). Western
blot shows expression of myc-GFP-TNRC6A wildtype (wt, lane 1 and 2) and NES-mut (lanes 3 and 4) with and without induction by tetracycline (Tet,
lanes 2 and 4) as detected using anti-Myc-Tag antibody. Tubulin was used as loading control. (B) Endogenous TNRC6B was detected in untreated or
Leptomycin B treated HeLa cells upon knockdown of Imp or transfection of a control siRNA. Diagram shows quantification of TNRC6B signal from
untreated or Leptomycin B-treated cells with or without knockdown of Imp. Nucleus-to-cytoplasm ratio was calculated from nuclear and cytoplasmic
TNRC6B signals. (C) Endogenous Ago2 was detected in HeLa cells and quantified as described in (B). Error bars represent standard error of the mean
(SEM). *P < 0.05. n.s., P > 0.05.
test Imp/–TNRC6 interactions, we performed in vitro
binding assays (Figure 5A–D). Since Imp can also affect
Imp’s binding affinity to cargo proteins (65,66), binding
of both proteins was analyzed. Different isoforms of GST-
Imp (1, 3, 4, 5 and 7) as well as GST-Impwere im-
mobilized and incubated with radiolabeled TNRC6A. Ei-
ther His-Imp was added to the Imp samples (Figure 5A)
or Imp was analyzed alone (Supplementary Figure S6).
Indeed, moderate binding of TNRC6A was observed for
the Imp isoforms in the presence Imp. In the absence,
however, binding was reduced (Supplementary Figure S6).
In addition, TNRC6A binding to Imp alone was read-
ily detectable indicating Imp-independent Imp contacts
to TNRC6A (Figure 5A, lane 6). Since our experiments
are not quantitative, conclusions regarding binding affini-
ties are not possible. To elucidate this observation further,
we performed binding experiments with TNRC6A contain-
ing mutations in a recently suggested NLS (49) (Figure 5B).
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Figure 5. Importin- and Importin- interact with TNRC6 proteins. (A) In vitro transcribed and translated TNRC6A was incubated with recombinant
GST alone (lane 1), GST-tagged Imp-family members and Imp-His (lanes 2–5) or Imp-GST alone (lane 6) followed by GST-pulldown. TNRC6A
was detected by autoradiography, recombinant proteins by Coomassie staining. Lane 7 shows input of TNRC6A. (B) In vitro transcribed and translated
TNRC6ANLS-mut (lanes 1–6) or TNRC6A (lane 7) was incubated with GST alone or the indicated Importins and pulled down as described in (A). Lanes
8 and 9 show inputs of TNRC6A and TNRC6ANLS-mut. (C,D) In vitro transcribed and translated TNRC6B (C) and TNRC6C (D) were incubated with
GST alone (lane 1) or the indicated Importins (lanes 2–6 in C and 2–7 in D) and pulled down as described in (A). Lane 7 in (C) and 8 in (D) show inputs
of TNRC6B or TNRC6C. All autoradiographs in (A–D) have been exposed simultaneously. (E) FH-Imp has been cotransfected with myc-GFP (lane 1
and 4) or myc-Ago2 (lanes 2 and 5) in HEK 293T cells or transfected into HEK 293T with stable inducible myc-GFP-TNRC6A cultivated in the presence
of Tetracycline (lanes 3 and 6). Myc-tagged proteins were immunoprecipitated from cytoplasmic extracts with anti-Myc antibody. Immunoprecipitations
were analyzed with anti-HA and anti-Myc antibodies. (F) Immunoprecipitations have been performed as described in (E), excluding myc-Ago2, in the
absence (lanes 1, 2, 6 and 7) or presence of increasing amounts of recombinant His-tagged RanQ96L, preincubated with GTP (lanes 3–5 and 8–10). (G)
HeLa cells were transfected with myc-GFP-TNRC6A, NLS-mut or NES-mut followed by treatment with Leptomycin B or control treatment. Diagram
shows percentage of cells with cytoplasmic or nuclear GFP foci or foci in both compartments (intermediate) with or without Leptomycin B treatment.
Western Blot shows expression of myc-GFP-TNRCA wildtype (wt, lane 2), NLS-mut (lane 3) and NES-mut (lane 4) as detected using anti-GFP antibody.
Untransfected (untransf.) cells were loaded as control and Tubulin was detected as loading control.
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Figure 6. Reciprocal cytoplasmic retention of TNRC6 and Ago2. (A) HeLa cells were cotransfected with myc-GFP-TNRC6A, NES-mut or GW-NES-
mut and FH-Ago2, Y529E, PAZ9 or empty plasmid (FH). TNRC6A and its mutants were detected by GFP signal (shown here in red), Ago2 and its
mutants with anti-HA antibody staining (shown in green). Diagrams on the right show percentage of cells with cytoplasmic or nuclear GFP foci or foci
in both compartments (intermediate). Ago2 PAZ9 is shown as diagram only. Western blots on the right show expression of FH-Ago2 and its mutants
(upper Blot) or myc-GFP-TNRC6A and its mutants (lower Blot). Tubulin was detected as loading control. (B) TNRC6A, TNRC6B and TNRC6C were
knocked down each on its own or simultaneously in HeLa cells and endogenous Ago2 was detected by anti-Ago2 antibody staining. A control siPool
served as negative control. Diagram on the right shows nucleus-to-cytoplasmic ratio of Ago2 by quantification of nuclear and cytoplasmic signals. Error
bars represent standard error of the mean (SEM). **P < 0.005.
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Figure 7. Ago2 blocks binding of Importin- and Importin- to TNRC6A. (A) In vitro transcribed and translated TNRC6A was incubated with recombi-
nant GST (lanes 1 and 2) or Imp-GST (lanes 3 and 4). Additionally, recombinant HA-Ago2 was added when indicated (even lanes). After GST-pulldown,
TNRC6Awas detected by autoradiography, recombinant proteins by Coomassie staining. Lane 5 shows TNRC6A input. (B) In vitro transcribed and trans-
lated TNRC6A was incubated with recombinant GST (lanes 1 and 2) or GST-tagged Imp-family members and Imp-His (lanes 3–12). Recombinant
HA-Ago2 was added when indicated (even lanes). Experiments were analyzed as described in (A). Lane 13 shows TNRC6A input. (C) Recombinant GST
(lane 2), GST-tagged TNRC6B 599–683 (lane 3), Imp3 (lane 4), Imp (lane 5) and Imp3 + Imp-His (lane 4) were incubated with HA-tagged recombi-
nant Ago2. After GST-pulldown, Ago2 was detected in input (lane 1) and pulldowns (lanes 2 to 7) by anti-HA antibody. Proteins in input and pulldowns
were additionally detected by Coomassie staining. (D) Coimmunoprecipitations with anti-Myc antibody were performed from HEK 293T cells coexpress-
ing Flag/HA-tagged Imp and myc-GFP (lane 1 and 6) or myc-GFP-TNRC6A (lanes 2 and 7). Additionally, GFP (lanes 3 and 8), GFP-Ago2 (lanes 4 and
9) orGFP-Ago2Y529E (lanes 5 and 10) were coexpressed. Immunoprecipitations were analyzed with anti-HA (FH-Imp), anti-Myc (myc-GFP-TNRC6A
and myc-GFP) and anti-GFP antibodies (GFP-Ago2 or GFP-Ago2 Y529E).
Binding of Imp to this mutant appeared to be weaker.
Binding to Imp, however, remained unaffected. Our data
suggest that the reported NLS contributes to nuclear trans-
port, potentially via Imp, but is not sufficient and addi-
tional TNRC6A elements are required.We next investigated
binding of the import proteins to TNRC6B and C (Figure
5C and D). Similarly to TNRC6A, Imp efficiently bound
TNRC6B and C. In contrast, binding to the Imp isoforms
was not observed (Figure 5C and D) consistent with the
finding that classical Imp-dependent NLS were not found
in TNRC6B and C (49).
To confirm our in vitro binding results, we performed
co-immunoprecipitation experiments (Figure 5E and F).
FH-Imp was co-transfected with myc-Ago2 or myc-GFP
as control into HEK 293 cells. For better expression lev-
els, myc-GFP-TNRC6A was stably transfected. Indeed,
FH-Impwas co-immunoprecipitated with anti-myc-GFP-
TNRC6A but not with myc-Ago2 or the control (Fig-
ure 5E). Furthermore, incubation of the immunoprecipi-
tates with RanQ69L, a Ran mutant that destabilizes Im-
portin – cargo interactions (67), interrupted with TNRC6A
binding to Imp (Figure 5F). Our binding experiments
therefore suggest that Imp interacts with TNRC6A in a
Ran-dependent manner.
To further validate the reported NLS, we performed
LMB treatment experiments (Figure 5G). While wild type
(wt) TNRC6A was trapped in the nucleus under these con-
ditions (upper panel), the NLS mutated variant was only
partially nuclear (middle panel). These observations sup-
port our model that the reported NLS is not sufficient
for TNRC6 import and so far unidentified Imp contacts
might exist. Taken together, we found that Imp facili-
tates transport of TNRC6 proteins into the nucleus presum-
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Figure 8. A model for nuclear transport of Argonaute and TNRC6 proteins. In the cytoplasm, Argonaute and TNRC6 proteins interact during miRNA-
guided gene silencing. Free Argonaute and TNRC6 proteins instead can shuttle between the nucleus and cytoplasm, which may contribute to balancing
cytoplasmic levels. Nuclear import of TNRC6 proteins is mediated by Imp (a). TNRC6A can additionally been imported via classical Imp/-mediated
import (b). Nuclear import of Ago proteins instead is non-classical, Imp-independent and probably mediated by several redundant import receptors.
Nuclear export of both Ago and TNRC6 proteins is mediated by Crm1. In the nucleus, Ago2 and TNRC6 can interact and co-localize, however, functions
of these P-body-like nuclear structures are not known.
ably via canonical, Imp-dependent processes or by direct
TNRC6 interactions.
Cytoplasmic Ago and TNRC6 levels influence nuclear local-
ization
Since TNRC6 and Ago proteins most likely reach the
nucleus via different pathways but form a cytoplasmic
complex, we next investigated whether Ago and TNRC6
proteins affect each other’s nuclear localization. We co-
expressed myc-GFP-TNRC6A NES-mut, which is trapped
in the nucleus, together with FH-Ago2 (Figure 6A). Strik-
ingly, myc-GFP-TNRC6A NES-mut exclusively localized
to the cytoplasm when high levels of Ago2 are present sug-
gesting that the presence of the binding partner retains
TNRC6A in the cytoplasm (Figure 6A, third row of im-
ages). This cytoplasmic retention appears to depend on
small RNA binding of Ago2 since Ago2-Y529E (68) (or
Ago2 PAZ9 (69), images not shown), which cannot bind
small RNAs, does not retain TNRC6A in the cytoplasm
(Figure 6A, fourth row of images). Furthermore, when the
Ago binding motif was mutated together with the NES
(TNRC6A GW-NES-mut), TNRC6A was not retained
in the cytoplasm indicating that indeed Ago binding is re-
sponsible for cytoplasmic retention (Figure 6A, sixth row
of images). Quantification and protein expression levels are
shown to the right. Vice versa, when endogenous TNRC6A,
B and C are knocked down simultaneously by a potent
siPool (62), nuclear Ago2 levels increase presumably due to
a lack of the interaction partner for silencing in the cyto-
plasm (Figure 6B, middle part, upper row). Knock down of
individual TNRC6 proteins had no effect on Ago2 localiza-
tion suggesting redundant TNRC6 protein function (Figure
6B, left part). Signal quantification is shown to the right.
SinceAgo expression affects nuclear import of TNRC6A,
we asked whether Imp/ and Ago2 binding are mutu-
ally exclusive. To test this hypothesis, GST-Imp was im-
mobilized and incubated with radiolabeled TNRC6A (Fig-
ure 7A). Indeed, addition of recombinant Ago2 strongly
reduced binding to TNRC6A suggesting that the binding
partners exclude each other. Similar results were obtained
when Imp isoforms were analyzed (Figure 7B). To exclude
binding of recombinant Ago2 to Imp or  in these assays,
we performed directAgo2 binding experiments (Figure 7C).
HA-Ago2 bound specifically to a TNRC6B peptide con-
taining the Ago interacting motif (TNRC6B 599–683) (11).
However, binding to Imp or  was not observed indicat-
ing binding to TNRC6 and not the import receptors in our
experiments (Figure 7A and B). Since Imp binding is in-
dependent of the investigated NLS, another NLS that is af-
fected by Ago binding is most likely present on TNRC6A
and the other TNRC6 proteins. To further support our in
vitro findings, we performed co-immunoprecipitation exper-
iments as described above (Figure 5E). FH-Imp was co-
immunoprecipitated with myc-GFP-TNRC6A. However,
co-expression of GFP-Ago2 inhibited binding of Imp to
TNRC6A. Consistent with our localization studies (Fig-
ure 6A), co-expression of themiRNA-binding deficient mu-
tant GFP-Ago2 Y529E did not compete with Imp bind-
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ing. Taken together, we have shown that both Ago2 and
TNRC6 proteins can influence each other’s nuclear levels
depending on the availability of the respective binding part-
ner in the cytoplasm.
DISCUSSION
Mammalian Ago proteins have been implicated in various
nuclear functions ranging from transcriptional silencing
and activation to DNA double strand break repair and al-
ternative splicing. However, their nuclear import pathways
remain elusive. In addition, nuclear localization of other cy-
toplasmic gene silencing factors has only poorly been inves-
tigated (5). Using several different methods, we show that
human Ago2 is indeed found in the nucleus. This has been
observed in a variety of publications before (46,48,70–71).
However, our analyses also suggest that only a minor por-
tion of Ago2 might be present in the nucleus under steady
state conditions. It is nevertheless possible that larger por-
tions of the Ago2 pool localize to the nucleus under con-
ditions that have not been analyzed here. For example, it
has been reported that Ago2 proteins are found in the nu-
cleus upon senescence induction (70). Using LMB treat-
ment, which blocks Crm1-mediated export, we show that
the nuclear pool of Ago2 increases suggesting that at least
a part of the Ago pool shuttles between the nucleus and the
cytoplasm. It is also conceivable, however, thatAgo proteins
use additional export routes, which we have not included in
our analyses (72). Shuttling also requires nuclear import.
The import receptor Imp8 has been implicated in the cy-
toplasmic function of miRNAs and it was reported that
it might also contribute to nuclear localization of mature
miRNAs and Ago proteins (50,51). However, by targeting a
nuclear RNA (7SK) (47), we find that knock down of Imp8
did not change Ago2-mediated cleavage of the nuclear tar-
get. Additionally, none of the other tested import receptors
resulted in a change of nuclear RNAi efficiency and there-
fore we suggest that these proteins might function redun-
dantly and several import receptors are capable of import-
ingAgo proteins into the nucleus. Such redundant transport
pathways have been found for several other nuclear factors
before including mammalian Dicer (60,63).
Similarly to Ago proteins, TNRC6 proteins localize pre-
dominantly to the cytoplasm under steady state condi-
tions. Using LMB treatment, all three TNRC6 proteins
are trapped in the nucleus suggesting shuttling and Crm1-
mediated export. This has been observed for TNRC6A
and B before (17,49). A recent report identified a NES on
TNRC6A and mutation of this signal sequence trapped
TNRC6A in the nucleus (49). Interestingly, over expressed
TNRC6ANES-mut forms P-body-like structures in the nu-
cleus. We characterized these structures further and found
that they do not resemble known nuclear structures (Sup-
plementary Figure S2). Also cytoplasmic P-body markers
are not recruited to these nuclear TNRC6 bodies. Only,
a minor portion of the nuclear Ago2 pool is occasion-
ally found in these structures. We therefore speculate that
TNRC6 proteins are capable of forming P-bodies indepen-
dently of any other cytoplasmic P-body component. This
also suggests that TNRC6 proteins might be scaffold pro-
teins within P-bodies probably forming a meshwork by
stacking interactions of the many GW pairs in their large
unstructured N-termini. A similar concept has been re-
ported for FG repeats in nucleoporins, which form a mesh-
work in the nuclear pore (73). However, this needs to be fur-
ther investigated.
We took advantage of the nuclear localization of the
TNRC6ANES-mut and found that Imp targets TNRC6A
into the nucleus. This import receptor does not affect Ago
nuclear localization indicating that both protein families
reach the nucleus via different pathways and are not co-
imported (Figure 7). During canonical nuclear import,
Imp binds directly to an NLS and is then bound by Imp,
which facilitates nuclear import (64). We find that Imp
binds to a previously identified NLS on TNRC6A. Addi-
tionally, Imp contacts TNRC6A independently of Imp
suggesting an Imp-dependent and –independent import
route. TNRC6B and C do not bind to Imp and are most
likely imported by Imp alone.
Interestingly, when over expressing Ago2 in the cyto-
plasm, even the TNRC6A NESmut version remains in the
cytoplasm suggesting that TNRC6 proteins travel through
the nucleus in case they are not needed for silencing in the
cytoplasm. Consistently, nuclear Ago pools increase, when
all three TNRC6 proteins are knocked down suggesting that
Ago proteins might be able to shift into the nucleus po-
tentially for storage or turn over. It is tempting to specu-
late that nuclear import contributes to balanced cytoplas-
mic Ago2 and TNRC6 protein levels (Figure 8). In con-
trast, we also observed that TNRC6 mutants, which cannot
bind Ago proteins, are still cytoplasmic (data not shown)
suggesting that not all unbound TNRC6 proteins are im-
mediately imported into the nucleus. Likewise, so far un-
known regulatory processes might exist that trigger TNRC6
or Ago import. For example, post-translational modifica-
tionsmight be involved in such regulatory events. This, how-
ever, remains to be investigated.
It is also conceivable that both TNRC6 and Ago proteins
possess gene silencing-independent functions in the nucleus
of human cells. In future work, it will be interesting to an-
alyze which proteins and RNAs associate with the nuclear
TNRC6 protein pool.
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Supplementary Data are available at NAR Online.
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